CanAssist Breast - a 'Made in India' test is helping patients to avoid non-beneficial chemotherapy

BANGALORE, India - Aug. 24, 2021 - PRLog -- Breast cancer is the commonest cancer and the leading cause of cancer-related mortality among Indian women. Approximately 95% of early-stage hormone receptor positive breast cancer patients in India get treated with chemotherapy but nearly 80% of them do not need it and bear severe toxic side effects resulting in poor quality of life. Accurate prediction of 'risk of recurrence' in such patients can aid to an effective treatment planning. CanAssist Breast (CAB) is a cost-effective prognostic test that helps to find if the patient needs chemotherapy or can simply avoid it.

CanAssist Breast is the first prognostic test to be developed using Indian patient's tumor tissues. All the competing prognostic tests have been developed on Caucasian patients which are not ideal for Asian patients due to differences observed relating to the onset and biology of the disease. CAB has been validated on nearly 1000 patients across India followed by the publication of results in a peer-reviewed international medical journal "The Breast". Additionally, it has also been validated in nearly 2000 patients across various countries including the US, Spain, Germany, Austria, Italy and The Netherlands.

As of date, CAB has been used to plan treatment on 1600+ patients in India, Sri Lanka and Bangladesh and nearly 70% of them have been saved of perhaps the non-beneficial chemotherapy. Interestingly, early data on patients who have finished 5 years since its use shows that CAB has 100% accuracy in its prediction.

Dr. Harit Chaturvedi, Chairman of Max Institute of Cancer Care in Delhi who has prescribed CAB to many of his patients says, "If you look at the sheer numbers, every 7 out of 10 patients who are eligible for a prognostic test can avoid chemotherapy. With a more affordable test like CanAssist Breast, one will see a large section of these patients cutting down on avoidable chemotherapy. The scientific maturity of our community also reflects well by bringing such a test into the practice. Validation of CanAssist is on our population database and everything is in the Indian context."

According to Dr. Manjiri Bakre(https://bit.ly/2UIIHtP), Founder and CEO of Oncostem Diagnostics, "This is a first of its kind test developed and validated on Indian patients and has received international accreditation. Furthermore, CanAssist Breast (https://bit.ly/3DaIr89) is accredited by ISO13485 and CE-IVD and the lab is CAP (College of American Pathologists) and NABL certified that adds to the quality and rigor with which the test is performed".
Reach us at info@oncostemdiagnostics.com. www.oncostem.com